Clinical Trial Update: The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated AZD8529 for effects on cognition and negative symptoms in people with schizophrenia. The trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• AZD8529

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED